Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0006142 (breast cancer)
 160,383 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

104 patients with various cancer, excluding malignant lymphoma and leukemia, underwent bone marrow biopsy using a Jamshidi needle, regular type. In 100 patients an adequate pice of bone marrow was obtained. In 24 patients metastases were detected in the bone marrow. Metastases were found in 10 of 38 (26.3%) patients with breast cancer, in 5 of 17 (29.4%) patients with lung cancer, in 5 of 10 (50%) patients with cancer of the prostate, in 1 patient with rhabdomyosarcoma, 1 with chordoma and in 2 of 14 patients who underwent biopsy in search of unknown cancer. 71% of the patients with positive findings in the bone marrow had clinical signs of bone involvement, 80% had positive X-ray film and 78.9% had positive skeletal isotope survey. Hemogram, serum alkaline phosphatase, serum calcium level and sedimentation rate were of no value in predicting whether the marrow was involved or not. No complications were documented following biopsy. The use of the Jamshidi bone marrow biopsy needle for staging and early detection of metastases in a select group cancer patients is suggested.
 ...
PMID:Bone marrow biopsy in patients with malignant neoplasms other than lymphomas or leukemia. 11 9

24 HL-A antigens were determined in a total of 163 Caucasien cancer patients (60 breast cancers, 64 cancers of the cervix uteri, 19 cancers of the endometrium and 20 cancers of the ovary). The comparison of the antigen frequencies with the analogous values from 1000 healthy controls yielded no outstandingly significant deviations for cancer of the cervix, endometrium and ovary. In breast cancer patients, however, there might be an association with the antigens HL-A10 and W18 or the haplotype HL-A10-W18, as indicated by the results of a combined evaluation of our data together with the results of four different HL-A studies in breast cancer patients.
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1975
PMID:HL-A antigens in carcinoma of the breast, ovarium, cervix and endometrium: possible association of haplotype HL-A10-W18 with carcinoma of the breast. 12 12

Evidence suggests that the reliability of urinary androgens or estrogens as prognostic discriminants for breast cancer may vary with different populations and may bear little relation to changes in plasma hormone levels. In this study the plasma estradiol level was significantly lower in Bantu, but did not in Caucasian, women with breast cancer, while the proportion of plasma androstenedione to dehydroepiandrosterone increased in Bantu patients. These changes in the plasma hormone profile in Bantu patients, a low-risk population for breast cancer, imply a change in ovarian and/or adrenal activity. Lack of similar hormone changes in Caucasian patients may be due to the initial differences in the hormone profile between the healthy Caucasian and Bantu women and to the different environmental factors that promote the breast disease in Western women.
Cancer Res 1976 Jun
PMID:Plasma hormone profiles in populations at different risk for breast cancer. 13 45

An increase in the number or the sudden appearance of multiple microcalcifications in the course of a mammographic controls series represent a further important sign of malignancy. In 14 of our cases witha non palpable breast cancer we were able to observe an increase in the number or a sudden appearance of typical calcium precipitates during an observation period, which, according to the case, lasted from 6 to 21 months. Biopsy revealed in all cases an early cancer. Our observations demonstrate the absolute indication for biopsy in all patients, which during a mammographic control series suddenly present microcalcifications, or an increase in the number of the ones that were previously observed. All patients showing clustered microcalcifications, which because of their small number are not demanding a biopsy, should be regarded as risk-cases and observed regularly in order to rule out or demonstrate an increase in the number of calcifications. Follow-up series within six months are recommended.
 ...
PMID:["Numeric increase of microcalcifications, an important radiologic sign of occult breast cancer" (author's transl)]. 13 69

It has been suggested that the urinary hormone profile is subject to environmental changes, such as urbanization and Westernization, and that the composition of the hormones can be used as a discriminate in determining the patient at risk for breast cancer. In this study, a comparison of the plasma hormone levels in Bantu and Japanese women, low-risk populations, and Caucasian women, a high-risk population, showed a higher level of 17 beta-estradiol in prepubertal girls and young Bantu and Japanese women. The higher estrogen level in the Bantu was evident in the early luteal and late follicular phases of the menstrual cycle. The difference in the dehydroepiandrosterone and testosterone levels in Bantu young women and prepubertal Bantu girls, suggests differences in adrenal activity between Bantu and Caucasian women. A fall in the plasma androstenedione was evident in postmenopausal Bantu and Japanese but not Caucasian women. Data suggest that the hormone profile is different among the 3 ethnic groups in both the pre- and postmenopausal women. Since the daily life-style of the women is comparable, it is suggested that the composition of the hormone profile is partially dependent on dietary on dietary factors.
Cancer Res 1976 Jul
PMID:Plasma hormone levels in different ethnic populations of women. 13 69

In a prospective study eleven patients with metastasizing breast cancer were treated with 5-fluorouracil, adriamycin, and cyclophosphamide )FAC). Complete remission occurred in three patients, with two of them still in remission four and thirteen months later. Partial remission (50% decrease in tumour size for more than four weeks) was achieved in five cases, with three of them still in remission. Time for remission induction was one to three months. The mean duration of complete remissions is not yet reached after thirteen months- that of partial remissions was 6.5 months. Two patients showed stable disease for four and more than eleven months, respectively. Only in one case progressive disease was noticed. Mean survival time from the start of therapy was 7.5 months for all patients. For complete and partial responders mean survival is not yet reached after eighteen months. With one exception therapy was given on an outpatient basis. Experimental and clinical data on therapeutic synergism of adriamycin, cyclophosphamide, and 5-fluorouracil show no advantage of the three-drug combination over the combination of adriamycin and cylophosphamide alone.
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1976 Jun 15
PMID:[Adriamycin, cyclophosphamide, and 5-fluorouracil in the treatment of metastasizing breast cancer (author's transl)]. 13 86

Lymphocyte proliferation assays with autologous tumor material in mixed leukocyte-tumor interactions (MLTI) were employed to monitor tumor-associated cell-mediated immune responses of peripheral blood lymphocytes from patients with carcinoma of the breast. In addition, leukocyte migration inhibition (LMI) assays were employed to compare reactivity to autologous breast-tumor extracts versus allogeneic breast-tumor extracts. Positive lymphoproliferative responses to tumor-associated antigens (TAA) were observed in the MLTI assay with the use of either intact autologous tumor cells or crude extracts (in mug and ng quantities) in 12 of 34 (35%) breast cancer patients studied. Positive reactivity to tumor, but not to normal tissue of reactive patients, was observed in repeated assays. Finally, patients demonstrating positive MLTI responses to autologous tumor extracts likewise responded in LMI assays to these same autologus extracts as well as to allogeneic breast-tumor extracts, but not to non-breast-tumor extracts. Thus breast tumors appeared to possess common TAA among both male and female patients.
J Natl Cancer Inst 1977 Mar
PMID:Cell-mediated immune responses of breast cancer patients to autologous tumor-associated antigens. 13 51

In women, dietary modification and life style affect the risk of breast cancer and may alter the hormonal status, while in experimental animals diet can alter the incidence of induced mammary tumors. In this study, a high fat diet increased the incidence of DMBA-induced tumors in rats while this increase in incidence was lowered and the effect of a high fat diet obliterated by an anti-prolactin during CB154. Premenopausal Japanese women had a higher estradiol level than their Caucasian counterpart. In Japanese but not Caucasian breast cancer patients, the estradiol decreased. When nurses were transferred from the Western to a vegetarian diet, the menstrual cycle was shortened, while their prolactin and testosterone decreased. Data indicate that dietary factors influence tumor incidence and hormone profile in rat mammary cancer and the hormonal status in women.
Cancer 1977 Apr
PMID:Diet and endocrine-related cancer. 14 2

Eighty one patients (59 females, 22 males) with advanced solid tumors were treated with Adriamycin in doses of 40 mg/m2 body surgace daily, in two days cycles, with resting periods of 3 weeks. Overall response rate was 46% (37/81). In breast cancer response rate was 56% (13/23) and in ovarian cancer 48% (13/27). In various other tumors remission was observed in soft tissue sarcomas (3/8), thyroid cancer (1/7), osteogenic sarcoma (1/4), oesophageal cancer (2/4), lung cancer (2/4), bladder cancer (1/2) and hepatoma (1/2). In breast cancer patients, 2-7 month remission duration was observed (M equal to 4.5 month) and in ovarian cancer 1.5-5 month (M equal to 3.2 month). Adriamycin was also applied intrapleurally in 31 patients with malignant pleural effusions with a low response rate (26%). This modified schedule of Adriamycin administration showed a high antitumor activity in breast and ovarian cancer and in soft tissue sarcomas. Squamous cell carcinoma of the esophagus was also sensitive to Adriamycin therapy. The very low rate of myelosuppression and oral ulceration showed the decreased toxicity of this Adriamycin administration schedule.
Z Krebsforsch Klin Onkol Cancer Res Clin Oncol 1977
PMID:Modified administration schedule of adriamycin in solid tumors. 14 May 42

The likely occurrence of two distinct types of human breast cancer is discussed. In the development of the "Western-environmental" or "adrenal" type, it is proposed that dehydroepiandrosterone sulphate (DHEAS), secreted by the adrenal, may be implicated. This steroid is metabolized by mammary tumors to active androgens and estrogens. That these metabolic pathways are very similar to that in skin is emphasized and this is possibly explained by evolution of the mammary gland from primitive sweat glands. Formation of DHEAS from DHEA in mammary tumors, claimed to be correlated with an individual subject's prognosis and response to hormone ablation, is discussed in the light of a possible regulatory role of the sulphotransferase. It is proposed furthermore that a specific control of DHEAS secretion in the adrenal may exist at the level of the sulphurylation step. Nutritional factors are also possibly implicated here and these are discussed in the light of: 1) a possible higher secretion rate of DHEAS in obese subjects; and 2) the low breast cancer incidence in the Japanese and the accompanying low blood DHEAS levels.
Cancer 1977 Jul
PMID:Steroid hormones and human breast cancer. An hypothesis. 14 76


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>